Role of endothelin in cyclosporine-induced glomerular dysfunction  by Kon, Valentina et al.
Kidney International, Vol. 37 (1990), pp. 1487—1491
Role of endothelin in cyclosporine—induced glomerular
dysfunction
VALENTINA KON, MASANORI SuGIuItk, TADASHI INAGAMI, BRADLEY R. HARVIE,
IEKUNI ICHIKAWA, and RICHARD L. HOOVER
Departments of Pediatrics, Biochemistry and Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Role of endothelin in cyclosporine-induced glomerular dysfunction.
Since recent studies indicate that cyclosporine (CsA) disrupts endothe-
hal integrity and that injured endothelial cells release excess endothelin,
we examined endothelin's role in acute cyclosporine nephrotoxicity.
Following CsA (20 mg/kg i.v.), rabbit anti-porcine endothelin (aE)
serum was continuously infused into a first order branch of the main
renal artery in Munich-Wistar rats whereupon the hemodynamics of
glomeruli not infused with aE as well as those infused with aE within
the same kidney were simultaneously assessed by micropuncture
techniques. In CsA treated kidneys, in glomeruli not infused with aE,
single nephron GFR (SNGFR) and glomerular plasma flow rate (QA) fell
profoundly (on average by 42 and 48%, respectively) below the baseline
values in association with lower glomerular capillary pressure and
elevated afferent arteriolar resistance. By contrast, in glomeruli infused
with aE within the same CsA treated kidneys, this vasoconstrictive
pattern was markedly attenuated: SNGFR was, on average, only 19%
lower than baseline and values for QA as well as other parameters
determining glomerular filtration were at or near the levels observed
before administration of CsA. In another group of rats (N = 6) an
identical dose of CsA was given to measure the circulating level of
endothelin. In these CsA treated rats, endothehin level (measured by
radioimmunoassay) was elevated at 41.7 14.7 pg/mI, contrasting the
value of < 2 pg/mI uniformly observed in identically instrumented
normal rats not given CsA (N = 5). Thus, cyclosporine is a potential
inducer for endothelin release and endothelin appears to have a pivotal
role in pathophysiology of cyclosporine-induced acute renal vasocon-
striction and glomerular dysfunction.
Cyclosporin A is an immunosuppressive agent, which has
become an integral component in the improvement of graft
survival of various organ transplants observed in the past
decade [1]. Although initially it was believed to be relatively
non-toxic [2], it is now apparent that it has a variety of adverse
effects, including hepatotoxicity, hypertension, and most im-
portantly, nephrotoxicity, which is now recognized to be so
pervasive that limitation for the use of the drug has been
proposed [3]. Renal dysfunction can occur at any time in the
course of treatment and is characterized by a spectrum of renal
involvement: from early, often reversible renal damage, to later
progression to it-reversible chronic renal failure. The early
reversible renal dysfunction is believed to reflect renal vaso-
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constriction and has been linked to altered renin-angiotensin
system, enhanced sympathetic tone, and impaired prostaglan-
din release [3—10]. Morphologically, capillary congestion and
arteriopathy with thrombosis is a well-recognized entity in
patients on cyclosporine [11]. In certain animal models, cyclo-
sporine causes endothelial injury and capillary thrombosis
similar to that seen in generalized Shwartzman reaction [7, 8].
Finally, a recent report showed direct toxicity of cyclosporine
in cultured rat microvascular endothelial cells whereby cyclos-
porine caused abnormalities in the cytoplasm and nucleus and
inhibited endothelial cell replication [10, 12]. Although there is
a wide spectrum of renal dysfunction with cyclosporine and
specific aspects of nephrotoxicity require study of different
animal models, taken together, these observations point to the
notion that cyclosporine is a potent toxic agent which adversely
affects endothelial cell metabolism and morphology.
Of interest in this regard, is accumulating evidence which
indicates that, in addition to PGI2, endothelial cells elaborate
other vasoactive substances including endothelial-derived Fe-
laxing factor and the powerful vasoconstrictor, endothelin [13].
Exogenous infusion of endothelin has been shown to cause
systemic hypertension and long-lasting constriction of vessels
in vitro and in vivo [13—16]. In addition, endothelin has recently
been found to have a pivotal role in the renal vasoconstriction
characteristic of post-ischemic renal failure [16]. Given the
notion that endothelin release is stimulated by endothelial stress
or injury, the present study examines whether the profound
renal vasoconstriction which occurs following acute cyclospo-
rifle administration can be attributed to the actions of endothe-
lin.
Methods
Experiments were done in male Munich- Wistar rats weighing
220 to 332 grams. The animals had been allowed access to
standard rat chow and tap water until the day of the experiment.
Group 1 animals (N = 8) were prepared for micropuncture as
previously described [16—l8]. Briefly, under mactin anesthesia
(70 mg/kg body wt i.p., BYK, Konstanz, FRG) tracheostomy
was performed, and indwelling polyethylene catheters were
inserted into femoral artery and vein and the jugular vein for
blood sampling, monitoring of systemic blood pressure, and
infusion of inulin and plasma to maintain euvolemia [16—18]. In
addition, one of the main branches of the left main artery was
gently isolated as previously described [16]. Care was taken not to
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disrupt the renal nerves and lymphatics. This vessel branch was
momentarily occluded (< 5 seconds) with fine forceps and
distribution of its blood flow marked on the surface of the
kidney with a permanent ink marker by noting the blanching of
the kidney surface. Using micropuncture techniques [16—18],
measurements and collections were made in two to three
nephrons located within the area supplied by the isolated
branch of the renal artery as well as two to three nephrons
outside of this area. Determination of SNGFR, hydraulic pres-
sures in glomerular capillaries (P0), proximal tubules (PT) and
efferent arterioles were made; also, femoral arterial (CA) and
efferent arteriolar (CE) plasma protein concentrations were
obtained permitting calculation of glomerular plasma flow rate
(QA), ultrafiltration coefficient (Kr) as well as resistances of
afferent (RA) and efferent (RE) arterioles. Colloid osmotic
pressure of plasma entering (VA) and leaving (ITE) glomerular
capillaries were estimated from CA and CE using derivations of
Deen et al [181. Details of the analytical procedure for inulin in
plasma and nanoliter tubule fluid samples, and that for CA and
CE are described elsewhere [16—181.
After baseline measurements and collections, each rat was
treated with cyclosporine (CsA). Cyclosporine (20 mg/kg, i.v.,
Sandoz Pharmaceuticals Co., East Hanover, New Jersey,
USA) was infused over 10 minutes. After 45 to 60 minutes, the
second period was begun, during which a portion of the kidney
was infused with anti-porcine endothelin serum (aE; Peptides
International, Louisville, Kentucky, USA) through one of the
branches of the renal artery. In a previous study, we showed
that in ischemia-injured kidneys, anti-endothelin serum, but not
non-immunized rabbit serum, infused into a branch of the main
renal artery improved glomerular hemodynamic function [161.
Furthermore, anti-endothelin serum caused no changes in sys-
temic or renal hemodynamics in normal rats. These results
attest to the specificity of the antiserum preparation used in
these experiments. A 1:10,000 dilution of the antiserum binds to
—50% of the radiolabelled endothelin at a concentration of 1.3
pmollml. The antiserum was diluted 1:100 with phosphate
buffer solution (pH 7.40) and infused at 0.9 mllhr. The infusion
of antiserum was accomplished through a sharpened micro-
pipette having an opening of —30 sm, mounted to a microma-
nipulator and connected by polyethylene tubing to a Harvard
Microinfusion Pump (Model #22, Cambridge, Massachusetts,
USA). The pipette was advanced through the wall of the
previously isolated branch of the renal artery. After 15 minutes
of antiserum infusion, micropuncture measurements and collec-
tions were repeated in nephrons of non-infused areas as well as
antiserum-infused regions of the kidney, The infusion pump
was calibrated in vitro [16]. Figure 1 schematically illustrates
the infusion technique which permitted sections of a kidney to
be presented with aE, while other parts of that same kidney are
not directly exposed to this substance. In a separate group of
rats (1A, N 5), we tested the effects on glomerular hemody-
namics of the vehicle for cyclosporine, Cremophor (polyoxyl-
ethylene castor oil and alcohol; Sandoz Pharmaceutical Co.).
The animals were prepared as those in Group 1. Micropuncture
collections were made before and 45 to 60 minutes after
systemic infusion of Cremophor in a volume identical to that
used in Group I, cyclosporine-infused rats.
Group 2 rats (N 6) were prepared similarly as for micro-







Fig. 1. Schematic illustration of the infusion technique which permits
various treatments of different populations of glomeruli in a kidney
treated with cyclosporine (CsA). Glomeruli I represent the glomeruli
following systemic infusion of CsA which were not infused with
endothelin antiserum, while Glomeruli 2 represent glomeruli from the
same CsA-exposed kidney which were infused with endothelin antise-
rum. These labels for the different nephron populations as well as
baseline values, which represent values obtained in glomeruli prior to
any experimental manipulation (CsA or anti-endothelin serum), are
given in Table 1, Fig. 2 and the text.
indwelling vascular lines. Each animal was infused with CsA
(20 mg/kg i.v.) for over 10 minutes, and blood pressure was
continuously monitored. Blood was harvested from the aorta
and immediately centrifuged at 4,000 rpm for 10 minutes at 0°C.
The serum was removed and stored at —70°C until assayed.
Group 2A (N = 5) was identical to Group 2 except, instead of
CsA, each rat received the identical volume of normal saline.
Endothelin measurements were performed by radioimmunoas-
say (RIA) as recently described by us [19]. Briefly, the standard
diluent for RIA was 0.1 M Tris-acetate (pH 7.4) containing 0.1%
BSA, aprotinin (500 KIU/ml, bovine lung, Sigma Chemical Co.,
St Louis, Missouri, USA), 1 ms'i EGTA, 0.02% sodium azide
and 0.1% Triton X-305. One hundred microliters of standard
endothelin or sample was incubated with 50 d of antiserum
(Peninsula Lab., Inc., Belmont, California, USA; final dilution
1:1.5 x 106) for 24 hours at 4°C, then 50 sl of iodinated
endothelin (15,000 to 20,000 cpm) was added to each tube and
incubated for 24 hours at 4°C. After the second 24-hour incu-
bation, 50 t1 of diluted (2%) normal rabbit plasma and 50 d of
diluted (0.25 unit) goat anti-rabbit IgG serum were added and
incubated for 24 hours at 4°C. The precipitate was collected
after centrifugation at 4,500 rpm for 30 minutes, washed once
with diluent buffer without Triton X-305, centrifuged at 4,000
rpm for 30 minutes and counted by Beckman Gamma 4000.
Statistics
Differences between periods in Group 1 were compared by
paired Student's t-test. Intergroup differences between Groups
2 and 2A were tested by analysis of variance with Bonferroni's
method [20]. Results were taken as statistically significant at P
<0.05.
Results
Table 1 summarizes systemic and microcirculatory parame-
ters before and after systemic infusion of cyclosporine as well
as effects of endothelin antiserum on glomerular hemodynamics
of cyclosporine-treated kidneys. Cyclosporine infusion caused
an increase in systemic blood pressure which began within
minutes of initiation of infusion and peaked within 10 to 15
minutes, whereupon it slowly returned toward the baseline
value. On average, the baseline value for blood pressure of 106
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Cyclosporine 109 41 27.2a iooa 46 12 2.94a 1.78 0.053
(Glomeruli 1) 2 4.4 19 1 1 0.53 0.32 0.011

















Micropuncture data (N = 8 rats) was obtained in nephrons prior to any experimental maneuver (baseline) and after intravenous infusion of
cyclosporine in glomeruli not exposed to anti-endothelin serum (aE) (Glomeruli 1) as well as nephrons exposed to aE (Glomeruli 2). Values are
expressed as mean SEM. Efferent arteriolar colloid osmotic pressure-to-glomerular transcapillary hydraulic pressure difference ratio was <1.0
in all rats during both periods and represent unique values for K1.
a Statistically significant differences (P < 0.05) between baseline and following cyclosporine or baseline and following cyclosporine in the
presence of anti-endothelin serum




2 (1 SE) mm Hg, peaked at 123 4 mm Hg (P < 0.0005) and
in the second period stabilized at 109 3 mm Hg (Table 1).
Systemic hypertension with cyclosporine treatment has previ-
ously been observed in similarly treated animals [21].
Within the kidney, while cyclosporine affected the microcir-
culatory parameters, remarkable differences were also ob-
served between nephrons infused with aE versus those neph-
rons not exposed to this substance (Table 1 and Fig. 2). In
Glomeruli 1 (exposed to cyclosporine but not to aE) the single
nephron GFR (SNGFR) fell from an average baseline value of
47.0 4.9 nhlmin to 27.2 4.4 (P < 0.01). A similar reduction
in GFR has previously been described with cyclosporine treat-
ment [4, 5]. By contrast, in Glomeruli 2 (exposed to cyclospo-
nne but also infused with aE) SNGFR remained substantially
higher, averaging 37.9 4.8 ni/mm. The glomerular plasma flow
rate, QA, also fell dramatically in response to cyclosporine: on
average from 192 38 nllmin to 100 19 in Glomeruli 1, but not
in Glomeruli 2 where it was 184 28. The marked hypoperfu-
sion and hypofiltration of Glomeruli 1 were reflected by signif-
icantly higher arteriolar resistances: values for afferent arterio-
lar resistance, RA, averaged 1.58 0.21 x 10'° dyn. sec/cm5
in the baseline period, and 2.94 0.53 in Glomeruli 1 following
infusion of cyclosporine. In Glomeruli 2, however, the RA
values averaged 1.61 0.23 x l0'°dyn . sec/cm5 following
cyclosporine, a value similar to that during baseline period.
There was no significant differences in the value for efferent
arteriolar resistance, RE, between baseline compared with
Glomeruli 1 or Glomeruli 2 (Table 1). No difference was
detected in the value of the glomerular capillary ultrafiltration
coefficient, Kf, in the two populations of glomeruli when
compared with the pre-cyclosporine levels (Table 1). In Group
lA animals (N = 5), systemic infusion of the vehicle for
cyclosporine, Cremophor, in a volume identical to that used in
Group 1 did not cause a uniform change in SNGFR, which on
the average decreased by 1.93 nL1min below the baseline value
(P > 0.1).'
In Group 2 rats, infusion of cyclosporine (20 mg/kg, i.v., N =
6) also increased the systemic blood pressure from an average
of 115 7 mm Hg to 133 22 mm Hg in a 10 to 15 minute
period. In one animal blood pressure fell from 90 mm Hg to 40
mm Hg; blood was obtained during the hypotensive period. The
endothelin level in all the animals was, on average, 41.7 14.7
pg/mI (hypotensive rat had endothelin level of 34 pg/mI). This
value is remarkably higher than the <2 pg/ml obtained in
identically prepared rats not receiving cyclosporine, Group 2A(N = 5; Fig. 3).
Discussion
In the present study, intravenous administration of a com-
mercially available, clinically used cyclosporine preparation
Previous studies noted that castor oil, which has been used as a
vehicle for cyclosporine causes dysfunction and histological changes
within the kidney [23, 24]. Difference between the current and previous
studies may relate to several factors including: the larger doses of
mineral oil used; the use of a continuous infusion of mineral oil; study
of the effects in an isolated perfused kidney; or differences in the route
of administration. It should be underscored that the Cremophor prep-















Fig. 2. Average percent change from baseline in the microcirculatory
parameters in cyciosporine treated kidneys within glomeruli infused
() and not infused (U) with anti-endothelin serum.














Fig. 3. Circulating levels of endothelin in cyclosporine treated and
control rats.
caused a virtually uniform increase in systemic blood pressure,
the increase beginning shortly after initiation of treatment. This
hypertensive response has previously been described in simi-
larly treated rats (intravenous cyclosporine, 10 mg/kg over 10
mm) [21]. In our study, hypertension progressively dissipated
and by the time of the micropuncture studies (-'--60 mm), blood
pressure had settled —3 mm Hg above baseline.
Within the renal microcirculation, the single nephron GFR
fell, on average, by some 40% below pre-cyclosporine values
(baseline vs. Glomeruli 1 in Table 1 and Fig. 2). This marked
decline in SNGFR was accompanied by a striking decrease in
glomerular plasma flow rate. Renal hypoperfusion is a familiar
finding in cyclosporine treatment and has been observed in
animals at variable time points during the course of cyclospo-
rifle treatment, from immediately after infusion to days and
weeks into cyclosporine treatment [4—6, 211. The lower glomer-
ular plasma flow rate was accompanied by higher renal vascular
resistance, particularly in afferent arteriole. In this regard,
English et al have recently provided anatomical correlates to
these functional observations [22]. Using scanning electron
microscopy of renal vascular casts, these workers demon-
strated focal narrowing in afferent arteriolar diameter which
progressed with time, so that after 14 days of cyclosporine the
entire afferent arteriole was narrowed (Note added in proof).
A remarkably different microcirculatory pattern was ob-
served in the same cyclosporine-treated kidneys, in glomeruli
which were infused with anti-endothelin serum. The SNGFR in
these aE-infused glomeruli (Glomeruli 2, Table 1 and Fig. 2)
was significantly higher than SNGFR in glomeruli of the same
kidneys not exposed to aE (Glomeruli 1), and were at a level
which was only 20% lower than pre-cyclosporine baseline
values. Similarly, glomerular plasma flow rate was higher in
aE-infused than aE-non-infused glomeruli, indicating restora-
tion of plasma flow rate in glomeruli exposed to endothelin
antiserum. These changes were reflected in lower arteriolar
resistances in Glomeruli 2 when compared with Glomeruli 1. A
study in a separate group of rats complemented these functional
data: administration of cyclosporine was observed to cause a
high circulating level of endothelin (Fig. 3).
Recent studies demonstrate that the potent constrictor effects
of systemic endothelin are not uniform among vascular beds of
different organs. Specifically, among coronary, bronchial, fem-
oral, and renal vascular beds, it was shown that the most
pronounced vasoconstrictor effects are seen in the renal circu-
lation [151. Thus, the kidney may be an important target organ
for endothelin. This echoes a familiar clinical observation that
cyclosporine, which is metabolized by the liver, has only
relatively modest hepatic toxicity [251, whereas its most trou-
blesome complication is nephrotoxicity. These findings empha-
size a predilection of cyclosporine to cause injury in the
kidneys.
It is currently believed that the nephrotoxicity with cyclo-
sporine largely reflects vascular phenomena [3—6]. There is little
doubt, however, that tubule dysfunction, either from direct
tubule toxicity or secondary to glomerular ischemia, contrib-
utes to renal dysfunction with cyclosporine. In support of the
notion that vascular injury is of utmost importance in early
cyclosporine toxicity are some, although not all, physiological
studies which show that antagonism of the renin-anigotensin
system [5], pharmacological blockade of the adrenergic tone or
renal denervation [4, 61 have been shown to improve renal
hemodynamics; furthermore, interference with vasodilating
prostaglandins can exacerbate renal vasoconstriction [4, 26].
The findings of intermediary role of a particular vasoactive
substance in cyclosporine toxicity do not necessarily preclude a
significant contribution of other(s) substances [27, 28]. Interre-
lationship between vasoactive agents is well recognized and
may include the newest recognized vasoconstrictor, endothelin.
In this regard, we recently found that enhancement in the renal
sympathetic tone increases the endothelin level in renal vein
blood and that infusion of endothelin antiserum ameliorates the
characteristic vasoconstriction associated with renal nerve
stimulation [29]. In the current study, since endothelin antise-
rum improved, but did not normalize, the hypoperfusion and
hypofiltration in cyclosporine-exposed kidneys, a contribution
of other factors is likely.
Morphological data of the renal vascular tree exposed to
cyclosporine reveals a spectrum of damage of varying severity.
The damage ranges from fulminant obliterating arteriopathy to
subtle changes within endothelial cytoplasm [301. It is of
interest that abnormalities in endothelial cells in cyclosporine
treated animals were detected early, before development of
more severe arteriopathic lesions [30]. In addition, it is well
known that cyclosporine can cause hemolytic-uremic syn-
drome-like lesions, which include abnormal endothelial cell
morphology [12]. Endothelial cells, therefore, appear to be a
primary target of cyclosporine-induced damage [11]. Support-
ing this notion are the recent studies showing that cyclosporine
directly damages endothelial cells in culture: cells were ob-
served to show early detachment, increased rate of cell lysis,
development of cytoplasmic vacuolization, and a decreased
rate of replication following exposure to cyclosporine [10, 12].
Moreover, cyclosporine has been shown to exacerbate renal
injury due to renal ischemia or infusion of endotoxin [31, 32],
two conditions now recognized to disturb the integrity of
endothelial cells. Both conditions were recently found by us to
involve endothelin in their pathophysiologic mechanisms [16,
191. Our studies with endotoxin showed that endothelin level is
remarkably higher in endotoxin-treated rats than normal ani-
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cultured endothelial cells significantly increases the endothelin
content in the culture media [191.
It is postulated then, that endothelial cell damage which
occurs with acute cyclosporine treatment may be the source of
the increased level of circulating endothelin. It is also possible
that both the increased circulating endothelin and intense
microvascular constriction following cyclosporine reflect pertu-
bations in local endothelin physiology, that is, overflow of
locally produced endothelin into the circulation, changes in
tissue content and local receptor characteristics for endothelin.
Since cyclosporine nephrotoxicity encompasses a spectrum of
renal damage which depends in part upon the length of treat-
ment it remains to be determined whether endothelin has a role
in chronic cyclosporine treatment.
Note added in proof
Using a vascular casting technique, it has recently been shown that
exogenous endothelin constricts afferent arteriole more than efferent
arteriole in hypertensive rats. HIRATA Y, MATsuoIc H, K1Mu& K,
FuKul K, HAYAKAWA H, SuzuKi E, SIJGIMOTO T, SUGIMOTO T,
YANAGISAWA M, MASAKI T: Renal vasoconstriction by endothelial
cell-derived peptide endothelin in spontaneously hypertensive rats.
Circ Res 65(5):1370—1379, 1989.
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